Cite

HARVARD Citation

    Wu, Y. et al. (2022). A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies. Drug discovery today. 27 (1), pp. 337-346. [Online]. 
  
Back to record